Comparing the current results to its competitors, Exelixis Inc reported Revenue increase in the 1 quarter 2026 by 9.97 % year on year. The revenue growth was below Exelixis Inc 's competitors' average revenue growth of 13.46 %, achieved in the same quarter.
Exelixis Inc Net Income in the 1 quarter 2026 grew year on year by 30.89%, while most of its competitors have experienced a contraction in net income by -30.97 %.
October 20, 2025
Exelixis, Inc. (Nasdaq: EXEL) has announced the results of a subgroup analysis from the CABINET phase 3 pivotal trial evaluating the efficacy of CABOMETYX (cabozantinib) against a placebo in patients with advanced neuroendocrine tumors (NET) originating in the lungs and thymus. The findings are scheduled to be presented during the Monday Poster Session: Neuroendocrine Tumours at the 2025 European Society for Medical Oncology Congress (ESMO), set to take place on October 20, 2025, from 12:00 to 12:30 PM.The CABINET trial was designed to ascertain the therapeutic benefits of CABOMETYX in a cohort of patients who had previously received treatment for advanced NETs. Specifically, this recent analysis focuses on ...
March 26, 2025
In a significant advancement in cancer treatment, Exelixis, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX (cabozantinib) for patients aged 12 years and older with previously treated advanced neuroendocrine tumors (NET). This approval marks a notable milestone in the management of well-differentiated pancreatic neuroendocrine tumors (pNET), as it provides new hope for patients with unresectable, locally advanced, or metastatic conditions.CABOMETYX, which is already recognized for its efficacy against various malignancies, will now cater to a new patient demographic struggling with this rare form of cancer. The FDA s endorsement is based on compelling clinical evide...
January 25, 2025
The biotechnology firm Exelixis, Inc. (Nasdaq: EXEL), based in Alameda, California, has made significant strides in both clinical and legal domains. Recently, the company revealed promising results from a subgroup analysis of its Phase 3 CABINET pivotal study. This study focused on the efficacy of Cabozantinib in treating advanced gastrointestinal neuroendocrine tumors (GI-NET). Equally noteworthy is Exelixis noteworthy victory in a separate legal dispute involving the defense of critical patents related to Cabozantinib against MSN Laboratories Private Limited. These dual advancements underscore Exelixis robust position both in the scientific and legal landscapes, further solidifying its prominence in canc...
October 15, 2024
In a significant development for the pharmaceutical industry, Exelixis, Inc. has achieved a favorable ruling in its ongoing patent litigation against MSN Laboratories Private Limited. The U.S. District Court for the District of Delaware found in favor of Exelixis, rejecting challenges posed by MSN Laboratories concerning three key patents listed in the Orange Book, which pertain to cabozantinib, a drug primarily used in the treatment of various cancers.The specific patents upheld by the court include U.S. Patent No. 11,091,439, which covers crystalline salt formulations of cabozantinib; U.S. Patent No. 11,091,440, pertaining to pharmaceutical compositions; and U.S. Patent No. 11,098,015. These patents are cr...
October 14, 2024
In a noteworthy collaboration, Exelixis, Inc. a prominent biotechnology firm, and Merck, an established giant in the pharmaceutical industry, have embarked on a clinical development partnership aimed at enhancing cancer treatment regimens. This collaboration integrates Exelixis investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck s renowned anti-PD-1 therapy KEYTRUDA (pembrolizumab), and promises to offer potential advancements in treating certain cancer types, particularly head and neck cancer and renal cell carcinoma.This partnership underscores a significant strategic alliance between the two companies, using their respective expertise to potentially improve patient outcomes in oncolo...
September 16, 2024
In a groundbreaking development for oncological pharmacotherapy, Exelixis, Inc. unveils compelling final results from its Phase 3 pivotal CABINET study, evaluating the efficacy of cabozantinib (trade name CABOMETYX) against placebo in patients with advanced neuroendocrine tumors (NETs). This pivotal trial focused on two specific cohorts: patients suffering from advanced pancreatic neuroendocrine tumors (pNET) and those with advanced extra-pancreatic NET (epNET), marking a significant stride in the targeted treatment landscape for these challenging malignancies.The findings, which were first presented at the 2024 European Society for Medical Oncology Congress (ESMO 2024) and subsequently published in the New ...
August 7, 2024
By MADISON, Wisc. Invenra, a leading biotherapeutics company, is celebrating a significant milestone with its collaboration partner, Exelixis, Inc. (NASDAQ: EXEL). Exelixis recently announced the initiation of the dose-escalation stage of the first-in-human Phase 1 clinical trial of XB010 in patients with locally advanced or metastatic solid tumors. This breakthrough marks the advent of a promising new therapeutic option under development. Introducing XB010: A New Hope for Cancer Therapy XB010 is an innovative antibody-drug conjugate (ADC) that showcases the latest advancements in targeted cancer therapy. The compound comprises a monomethyl auristatin E (MMAE) payload, which is a potent cytotoxic agent,...
May 20, 2024
In an announcement today, biotechnology company Exelixis, Inc. revealed that it has successfully settled a patent dispute with pharmaceutical firm Cipla Ltd. and its subsidiary Cipla USA, Inc. This settlement comes as a response to Cipla s Abbreviated New Drug Application (ANDA), which aimed to gain approval for the production and sale of generic versions of Exelixis flagship drug, CABOMETYX (cabozantinib) tablets, before the expiration of relevant patents. This resolution marks a significant victory for Exelixis, ensuring continued market exclusivity and the preservation of its intellectual property rights.Background:Exelixis, Inc., a Nasdaq-listed company headquartered in Alameda, California, specializes ...
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Springworks Therapeutics Inc is a biopharmaceutical company with a focus on developing innovative medicines for underserved patient populations. Their business model revolves around identifying promising therapeutic candidates, which could address significant unmet needs, and advancing them through various stages of clinical development. They collaborate with academic institutions, research organizations, and industry partners to accelerate the discovery and development of potential treatments, ultimately aiming to bring these therapies to market and improve patient outcomes.
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Titan Pharmaceuticals Inc is a biopharmaceutical company that operates through a licensing business model. They focus on the development and commercialization of proprietary therapeutics for the treatment of different diseases and disorders. By licensing their products to strategic partners, they aim to leverage their technology and expertise for the commercial success of their pharmaceuticals.
Sources:
Exelixis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Exelixis Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
